Genmab
Genmab Exercises Option for Second Commercial License Agreement with Scancell Holdings
Genmab, Scancell Holdings, monoclonal antibody, GlyMab platform, licensing agreement, cancer treatment, immunotherapies
Genmab Streamlines Portfolio by Cutting Early-Stage Oncology Assets
Genmab, oncology, early-stage candidates, portfolio optimization, Phase 3 projects
Genmab Streamlines Operations by Cutting 3 Early-Stage Programs to Boost Phase 3 Pipeline
Genmab, biotech, clinical programs, phase 3 pipeline, strategic focus
FDA Approval Milestones: X4 Pharmaceuticals, Pfizer, and Genmab Secure Nods for Rare Disease and Cervical Cancer Treatments
FDA, X4 Pharmaceuticals, Pfizer, Genmab, rare disease, cervical cancer, drug approval, treatment, healthcare, biotechnology.
Genmab Acquires ProfoundBio for $1.8 Billion to Challenge AbbVie’s Elahere in ADC Market
Genmab, ProfoundBio, $1.8 billion acquisition, Antibody Drug Conjugates (ADCs), Competition with AbbVie’s Elahere, Rinatabart sesutecan (Rina-S), Folate Receptor Alpha (FRα), Midphase clinical trials